Preclinical model drawbacks dampen UK innovation, ABPI report says
A report from the Association of the British Pharmaceutical Industry (ABPI) has suggested that a disharmony between academia and industry …
Post
-
-
Lundbeck’s migraine prevention drug meets primary endpoint in Phase IIb trial
Lundbeck’s migraine prevention drug has shown success in a Phase IIb trial, setting the company up for a Phase III …
-
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win
BridgeBio is heading to regulators after its achondroplasia therapy, infigratinib, met its primary and secondary endpoints in a pivotal study. During …
-
Centivax begins participant dosing in Phase Ia flu vaccine trial
Centivax has commenced participant dosing in its Phase Ia clinical trial, assessing Centi-Flu 01, a pan-influenza universal vaccine for flu. The …
-
Lyell doses first patient in Phase III trial for LBCL
Lyell Immunopharma has dosed the first patient in its PiNACLE – H2H Phase III chimeric antigen receptor (CAR)-cell trial for …
-
Obesity associated with increased infectious disease risk
According to the World Health Organization, approximately one in eight people worldwide was living with obesity in 2022. Obesity is …
-
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data
Upstream Bio’s stock value took a 47% downturn following the debut of topline results from a Phase II trial on …
-
Precision gains FDA approval to begin Phase I/II FUNCTION-DMD trial
Precision BioSciences has received a Study May Proceed notification from the US Food and Drug Administration (FDA), permitting initiation of …
-
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial
Senti Biosciences has completed enrolment of patients in its Phase I clinical trial assessing SENTI-202 in adults with relapsed or …
-
Evommune’s stock rallies 70% on Phase IIa eczema data
Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% …
-
How new technologies could transform clinical trial execution
Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation of processes and …
-
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win
Nektar Therapeutics stock has rallied 51% after its lead asset, rezpeg (rezpegaldesleukin), demonstrated potential across monthly and quarterly maintenance dosing …
-
Aardvark gains IRB approval for ARD-101 trial to treat Prader-Willi Syndrome
Aardvark Therapeutics has received Institutional Review Board (IRB) approval in the US for an amended protocol to its Phase III …
-
BioRestorative concludes Phase II BRTX-100 trial enrolment for cLDD
BioRestorative Therapies has concluded patient enrolment in its Phase II study evaluating the efficacy and safety of BRTX-100 for chronic …
-
AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials
As the oral weight-loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its candidate …
